PTGX
Protagonist Therapeutics, Inc.
Stock
$140.06+0.87 (+0.63%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $282M | $46M | $434M | $60M | $27M | $27M | $29M | $231K | $31M | $20M |
| R&D | $175M | $159M | $138M | $120M | $126M | $126M | $75M | $65M | $59M | $46M |
| Operating income | $58M | −$158M | $253M | −$94M | −$131M | −$126M | −$65M | −$81M | −$42M | −$38M |
| Non-operating income | $26M | $29M | $27M | $15M | $4.0M | $294K | −$329K | $2.6M | $2.5M | $940K |
| Pretax income | $84M | −$129M | $279M | −$79M | −$127M | −$126M | −$65M | −$78M | −$40M | −$37M |
| Taxes | $1.4M | $838K | $4.2M | $0 | $0 | $0 | $1.3M | −$691K | −$799K | $0 |
| Net income | $83M | −$130M | $275M | −$79M | −$127M | −$126M | −$66M | −$77M | −$39M | −$37M |
| Diluted EPS | $1.03 | −$2.05 | $4.23 | −$1.39 | −$2.60 | −$2.71 | −$1.92 | −$2.98 | −$1.74 | −$2.09 |
| Diluted shares | — | 63.6M | 65.1M | 56.8M | 49.0M | 46.3M | 34.4M | 25.9M | 22.4M | 17.7M |
| Revenue growth | — | −89.4% | +624.1% | +125.7% | −2.8% | −4.4% | +12,293.1% | −99.3% | +54.1% | — |
| Operating margin | 20.7% | −343.6% | 58.2% | −156.1% | −494.2% | −460.0% | −225.4% | −34,857.6% | −136.7% | −188.9% |
| Net margin | 29.4% | −282.8% | 63.3% | −131.6% | −479.3% | −458.9% | −231.1% | −33,414.3% | −125.9% | −184.2% |